Abstract: Objective: Observe and value the efficacy of postoperative chemotherapy for gastric cancer under the guidance of CD-DST Technology. Discuss its guiding role and feasibility for chemotherapy of gastric cancer. Methods: The patients who have been confirmed to be effective in vitro with FOLFOX4 by CD-DST enter pilot group， and the patients who have accepted FOLFOX4 without CD-DST enter control group. Compare postoperative one year and three years survival rate between the two groups. Results: In pilot group, year survival rate was 93.5%; three-year survival rate was 83.9%. In control group, year survival rate was 88.6%; three-year survival rate was 60.0%. The difference of three-year survival rate between two groups is significant in statistics. (P﹤0.05) Conclusion: CD-DST technology has some significance for the choice of chemotherapy program for individual treatment of gastric cancer patients.